Time: 16:15

MRCF and Uniseed…

Innavac, a biotechnology company spun out of the University of Melbourne that is developing novel, synthetic Toll-like receptor (TLR) agonists as therapies for the prevention and treatment of respiratory infections, has secured $6.3 million venture capital support from the Brandon…

Read More...
MRCF and Uniseed invest in respiratory start-up…
Innavac, a biotechnology company spun out of the University of Melbourne that is developing novel,…

Digital health leads…

With digital health industry forming and growing quickly across the traditional life sciences space, investment in the area is shaping up actively with a record number of companies funded with ‘seed’ and ‘series A’ investments. Digital health companies in the…

Read More...
Digital health leads the way…
With digital health industry forming and growing quickly across the traditional life sciences space, investment…

PharmAust reports preliminary…

PharmAust (ASX:PAA) says it has received preliminary analysis from its Phase 2 dog lymphoma trial that showed three out of four dogs treated with Monepantel (MPL) achieved stable disease and reduction in tumour size. The company said it is the first…

Read More...
PharmAust reports preliminary results from Monepantel trial…
PharmAust (ASX:PAA) says it has received preliminary analysis from its Phase 2 dog lymphoma trial…

Latest News

23 May 2017Latest News

MRCF and Uniseed invest in respiratory start-up Innavac

Innavac, a biotechnology company spun out of the University of Melbourne that is developing novel, synthetic Toll-like receptor (TLR) agonists…

23 May 2017AusBiotech

Digital health leads the way…

With digital health industry forming and growing quickly across the…

23 May 2017Company News

PharmAust reports preliminary results from Monepantel trial…

PharmAust (ASX:PAA) says it has received preliminary analysis from its…

23 May 2017Company News

Avita Board takes fees as shares

The Board of regenerative medicine company Avita Medical (ASX:AVH) has agreed to take part or all of their Director’s fees in…

23 May 2017Company News

Paradigm welcomes new publication

Paradigm Biopharmaceuticals (ASX:PAR) has announced the peer reviewed publication validating the efficacy…

18 May 2017Company News

Patient treatment commences in Cynata clinical trial

Australian stem cell and regenerative medicine company, Cynata Therapeutics (ASX:CYP), has…

18 May 2017AusBiotech

Business plan competition for tech startups

Startups are invited to apply for the “Sunan Cup” Startup…

18 May 2017Company News

Specialised Therapeutics adds compound to portfolio

Melbourne-based Specialised Therapeutics Asia (ST Asia) is set to commercialise a new anti-cancer drug in South East Asia after signing a…

18 May 2017Latest News

PharmAust secures broad patent coverage for non-cancer…

PharmAust (ASX:PAA), a clinical-stage oncology company, has announced the grant  of…